Literature DB >> 20877764

Rheumatoid arthritis.

Gene-Siew Ngian1.   

Abstract

BACKGROUND: Rheumatoid arthritis is a chronic disease that can cause irreversible joint damage and significant disability. With a prevalence of 1%, it has a considerable cost to the community. Diagnosis is based on a combination of clinical and laboratory features. Patients typically present with a symmetrical polyarthritis of the small joints of the hands and feet accompanied by early morning stiffness and, occasionally, constitutional symptoms.
OBJECTIVE: This review discusses the role of the general practitioner in the diagnosis and early management of rheumatoid arthritis. DISCUSSION: It is increasingly recognised that there is a 'window of opportunity' within which disease modifying antirheumatic drug therapy should be commenced to arrest progressive disease and joint destruction. Methotrexate is usually the first line agent in the management of rheumatoid arthritis but simple analgesia and nonsteroidal anti-inflammatory drugs are also important for symptom control.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20877764

Source DB:  PubMed          Journal:  Aust Fam Physician        ISSN: 0300-8495


  28 in total

1.  Mesenchymal stromal cells versus betamethasone can dampen disease activity in the collagen arthritis mouse model.

Authors:  E S M El-Denshary; L A Rashed; M Elhussiny
Journal:  Clin Exp Med       Date:  2013-08-30       Impact factor: 3.984

2.  Evaluation of the effects of different supplementation on oxidative status in patients with rheumatoid arthritis.

Authors:  Dragan Vasiljevic; Mirjana Veselinovic; Maja Jovanovic; Nevena Jeremic; Aleksandra Arsic; Vesna Vucic; Aleksandra Lucic-Tomic; Sandra Zivanovic; Dragan Djuric; Vladimir Jakovljevic
Journal:  Clin Rheumatol       Date:  2016-01-13       Impact factor: 2.980

3.  Suppressive effects of N-acetyl-D-glucosamine on rheumatoid arthritis mouse models.

Authors:  Kazuo Azuma; Tomohiro Osaki; Takashi Wakuda; Takeshi Tsuka; Tomohiro Imagawa; Yoshiharu Okamoto; Saburo Minami
Journal:  Inflammation       Date:  2012-08       Impact factor: 4.092

4.  Collagen-induced arthritis: severity and immune response attenuation using multivalent N-acetyl glucosamine.

Authors:  J Richter; K Capková; V Hříbalová; L Vannucci; I Danyi; M Malý; A Fišerová
Journal:  Clin Exp Immunol       Date:  2014-07       Impact factor: 4.330

5.  Norisoboldine alleviates joint destruction in rats with adjuvant-induced arthritis by reducing RANKL, IL-6, PGE(2), and MMP-13 expression.

Authors:  Zhi-feng Wei; Xiao-lan Jiao; Ting Wang; Qian Lu; Yu-feng Xia; Zheng-tao Wang; Qing-long Guo; Gui-xin Chou; Yue Dai
Journal:  Acta Pharmacol Sin       Date:  2013-02-11       Impact factor: 6.150

6.  Sorafenib Reveals Anti-Arthritic Potentials in Collagen Induced Experimental Arthritis Model.

Authors:  Nevzat Gözel; Maşallah Çakirer; Ahmet Karataş; Mehmet Tuzcu; Fethi Ahmet Özdemir; Adile Ferda Dağli; Kazım Şahin; Süleyman Serdar Koca
Journal:  Arch Rheumatol       Date:  2017-11-27       Impact factor: 1.472

7.  MLL3 Inhibits Apoptosis of Rheumatoid Arthritis Fibroblast-Like Synoviocytes and Promotes Secretion of Inflammatory Factors by Activating CCL2 and the NF-κB Pathway.

Authors:  Wenqiang Fan; Zhendan Xu; Shu Liang; Shufei Zuo; Caiyue Bian; Xiao Gao; Yilu Qin; Jie Wu
Journal:  Inflammation       Date:  2021-04-29       Impact factor: 4.092

8.  The future of rheumatoid arthritis and hand surgery - combining evolutionary pharmacology and surgical technique.

Authors:  Malahias M; Gardner H; Hindocha S; Juma A; W Khan
Journal:  Open Orthop J       Date:  2012-02-23

9.  Identification of hub genes in rheumatoid arthritis through an integrated bioinformatics approach.

Authors:  Rui Wu; Li Long; Qiao Zhou; Jiang Su; Wei Su; Jing Zhu
Journal:  J Orthop Surg Res       Date:  2021-07-16       Impact factor: 2.359

10.  Norisoboldine suppresses osteoclast differentiation through preventing the accumulation of TRAF6-TAK1 complexes and activation of MAPKs/NF-κB/c-Fos/NFATc1 Pathways.

Authors:  Zhi-Feng Wei; Bei Tong; Yu-Feng Xia; Qian Lu; Gui-Xin Chou; Zheng-Tao Wang; Yue Dai
Journal:  PLoS One       Date:  2013-03-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.